NCT06615609 "Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft Patients or Post Percutaneous Coronary Intervention Patients
| NCT ID | NCT06615609 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China National Center for Cardiovascular Diseases |
| Condition | Post Coronary Artery Bypass Grafting |
| Study Type | INTERVENTIONAL |
| Enrollment | 536 participants |
| Start Date | 2025-09-24 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 536 participants in total. It began in 2025-09-24 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to evaluate the effect of an AI-assisted "Smart family doctor" digital health management tool on improving the control rates of hypertension, diabetes, and dyslipidemia in post-CABG (coronary artery bypass grafting) patients or post-PCI (percutaneous coronary intervention) patients. A randomized controlled trial design will be used, involving approximately 5-10 hospitals and 536 participants. Eligible participants are adults aged 18 or older, post-CABG or post-PCI patients with hypertension, diabetes, and dyslipidemia.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * History of CABG surgery or PCI with history of hypertension, diabetes, and dyslipidemia. * At least one of the following criteria is meet: * Systolic blood pressure no less than 130 mmHg or diastolic blood pressure no less than 80 mmHg * HbA1c no less than 7% * LDL-C no less than 1.4 mmol/L * Use of a smartphone. * Signed informed consent. Exclusion Criteria: * History of heart failure or severe arrhythmias. * Presence of other severe underlying conditions such as cancer or liver and kidney insufficiency. * Pregnancy, lactation, or plans for pregnancy within the next year. * Cognitive, communication impairments, or limitations in daily activities.
Contact & Investigator
Xin Yuan, PhD
PRINCIPAL INVESTIGATOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Frequently Asked Questions
Who can join the NCT06615609 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Post Coronary Artery Bypass Grafting. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06615609 currently recruiting?
Yes, NCT06615609 is actively recruiting participants. Contact the research team at zhanglihua@fuwai.com for enrollment information.
Where is the NCT06615609 trial being conducted?
This trial is being conducted at Ürümqi, China.
Who is sponsoring the NCT06615609 clinical trial?
NCT06615609 is sponsored by China National Center for Cardiovascular Diseases. The principal investigator is Xin Yuan, PhD at Chinese Academy of Medical Sciences, Fuwai Hospital. The trial plans to enroll 536 participants.